Non-Monetary Consideration. Clause 9.5 applies to non-monetary consideration.
Non-Monetary Consideration. If a supply made under this Agreement is a Taxable Supply made for non-monetary consideration then:
Non-Monetary Consideration. If the consideration to Lessor for this Lease is the public use, benefit, health, or safety, Lessor shall have the right to review such consideration at any time and set a monetary rental if the Lessor, at its sole discretion, determines that such action is in the best interest of the State. Xxxxxx’s assignment or transfer of this Lease pursuant to Section 3 Paragraph 11 below to any third party which results in royalties, profits, or any form of compensation, whether monetary or otherwise, shall give Lessor the right to reevaluate the requirements of this Lease as stated in Section 3 Paragraph 11. Lessee shall be given at least thirty (30) days’ notice prior to the date of the Commission meeting wherein the rent modification is considered, or thirty (30) days’ notice prior to the effective date that this Lease is converted to a monetary rental, whichever provides more notice.
Non-Monetary Consideration. Neither Party shall sell a Product for any consideration other than cash except on terms specified in the Annual Commercialization Plan then in effect. In the event a Party receives any non-monetary consideration in connection with the sale of a Product or Competing Product, such Party’s payment obligations under this Article 8 or Section 7.6, as applicable, shall be based on the fair market value of such other consideration. In such case, the selling Party shall disclose the terms of such arrangement to the other Party and the Parties shall endeavor in good faith to agree on such fair market value.
Non-Monetary Consideration. If Licensee (or its Affiliates or Sublicensees) receives any form of consideration other than monetary consideration in connection with the Commercialization of the Product, including, by way of example, obtaining more favorable pricing for Licensee (or Affiliates or its Sublicensees) on other products, Bayer shall be entitled to payments hereunder based on the reasonable value of such consideration, the dollar amount of which shall be included in the calculation of Net Sales for purposes of calculating royalty payments under Sections 6.4 and 6.5.2 of this Agreement, as if it were payment in cash for sales of the Product.
Non-Monetary Consideration. In the event BMS (or its Affiliates or sublicensees) receives any non-monetary consideration in connection with the sale or other commercial disposition of Products, Athersys’s royalty shall be based on the fair monetary value of such other consideration. In such case, BMS shall disclose to Athersys, on a confidential basis, the terms of such arrangement, and the Parties shall agree in good faith on such monetary value, which shall then be included in Net Sales for the period in which it was received by BMS (or its Affiliates or sublicensees).
Non-Monetary Consideration. In the event that BMS or its Affiliate or sublicensee receives any non-monetary consideration in connection with the sale of a Product, BMS’ payment obligations under this Article 8 shall be based on the fair market value of such other consideration. In such case, BMS shall disclose the terms of such arrangement to EPC and EXEL and the Parties shall endeavor in good faith to agree on such fair market value.
Non-Monetary Consideration. Nuvectis shall neither enter into any agreement, nor permit any agreement to be made, under which any non-monetary Net Sales and/or Sub-Licensee Revenues are obtained or due to be obtained by Nuvectis and/or its Affiliates and/or its Sub-Licensees, except with prior written notification to the University. Where Nuvectis and/or its Affiliates accepts Sub-Licensee Revenues in the form of shares, Nuvectis shall, if so requested by the University, pay the royalty due under this Agreement on such Sub-Licensee Revenues by causing the appropriate percentage number of such shares to be transferred to, and registered in the name of the University’s nominee (Edinburgh Technology Fund Limited or such other notified entity). If the Parties disagree as to the cash value of any non-monetary receipt, such disagreement shall be referred to the Expert.
Non-Monetary Consideration. In the event Sanofi receives any non-monetary consideration in connection with the sale of a Licensed Product, Sanofi’s payment obligations under this Article 8 shall be based on the fair market value of such other consideration. In such case, Sanofi shall disclose the terms of such arrangement to KaloBios and the Parties shall endeavor in good faith to agree on such fair market value.
Non-Monetary Consideration. If Cxxx, its Affiliate or sublicensee receives any non-monetary consideration in connection with the commercial sale of Product, Cxxx’x payment obligation under Section 5.4 shall be based on the fair market value of such other consideration
